Amgen, Inc. (AMGN)
467.06
-1.05
(-0.22%)
USD |
NASDAQ |
Nov 12, 16:00
469.13
+2.07
(+0.44%)
After-Hours: 04:46
Amgen Net Income (Quarterly) : 3.864B for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 3.864B |
| June 30, 2026 | 2.375B |
| March 31, 2026 | 1.819B |
| December 31, 2025 | 1.333B |
| September 30, 2025 | 3.216B |
| June 30, 2025 | 1.432B |
| March 31, 2025 | 1.73B |
| December 31, 2024 | 627.00M |
| September 30, 2024 | 2.83B |
| June 30, 2024 | 746.00M |
| March 31, 2024 | -113.00M |
| December 31, 2023 | 767.00M |
| September 30, 2023 | 1.73B |
| June 30, 2023 | 1.379B |
| March 31, 2023 | 2.841B |
| December 31, 2022 | 1.616B |
| September 30, 2022 | 2.143B |
| June 30, 2022 | 1.317B |
| March 31, 2022 | 1.476B |
| December 31, 2021 | 1.899B |
| September 30, 2021 | 1.884B |
| June 30, 2021 | 464.00M |
| March 31, 2021 | 1.646B |
| December 31, 2020 | 1.615B |
| September 30, 2020 | 2.021B |
| Date | Value |
|---|---|
| June 30, 2020 | 1.803B |
| March 31, 2020 | 1.825B |
| December 31, 2019 | 1.703B |
| September 30, 2019 | 1.968B |
| June 30, 2019 | 2.179B |
| March 31, 2019 | 1.992B |
| December 31, 2018 | 1.928B |
| September 30, 2018 | 1.859B |
| June 30, 2018 | 2.296B |
| March 31, 2018 | 2.311B |
| December 31, 2017 | -4.264B |
| September 30, 2017 | 2.021B |
| June 30, 2017 | 2.151B |
| March 31, 2017 | 2.071B |
| December 31, 2016 | 1.935B |
| September 30, 2016 | 2.017B |
| June 30, 2016 | 1.87B |
| March 31, 2016 | 1.90B |
| December 31, 2015 | 1.80B |
| September 30, 2015 | 1.863B |
| June 30, 2015 | 1.653B |
| March 31, 2015 | 1.623B |
| December 31, 2014 | 1.294B |
| September 30, 2014 | 1.244B |
| June 30, 2014 | 1.547B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.429B |
| Regeneron Pharmaceuticals, Inc. | 1.949B |
| AbbVie, Inc. | 4.207B |
| Biogen, Inc. | -20.60M |
| Vertex Pharmaceuticals, Inc. | 653.60M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.36B |
| Total Expenses (Quarterly) | 6.497B |
| EPS Diluted (Quarterly) | 7.077 |
| Enterprise Value | 293.45B |
| Gross Profit Margin (Quarterly) | 73.09% |
| Profit Margin (Quarterly) | 37.29% |
| Earnings Yield | 3.69% |
| Operating Earnings Yield | 5.46% |
| Normalized Earnings Yield | 4.022 |